How to Negotiate a Korean ODM Quote: 9 Lines With Bargaining Room
By the ALTA MEET editorial team | K-beauty ODM consulting | NYC × Seoul Reviewed for accuracy by ALTA MEET's formulation and sourcing team
A founder shared her first Korean ODM quote with us last spring. Two SKUs, 3,000 units each, around $4.70 per unit blended, $42,000 in formulation work, packaging that ran a clean $1.80 over benchmark. She wrote back to the Seoul product manager with "this looks great, when can we start" and signed the deposit invoice three days later.
She left somewhere between $9,000 and $14,000 on the table. Not because the ODM was unfair. Korean ODMs price quotes the way most experienced manufacturers do, with a few lines that are basically negotiable and a few lines that are not. The founder did not know which were which, so she paid full freight on both.
This guide is the playbook ALTA MEET uses when we read an indie K-beauty founder's first Korean ODM quote alongside them. There are nine line items where indie founders have real bargaining room in 2026. There are four lines that are essentially fixed and where pushing only burns goodwill. We walk through both lists, the actual language to use, the three signals that mean the partner is wrong for you regardless of price, and the common mistakes that cost first-time founders unit cost before they ever ship.
The numbers and ranges in this piece reflect roughly 70 indie K-beauty quote sheets we have read alongside founders in the past 14 months. Cosmax, Kolmar, CTK Cosmetics, Cosmecca, and the boutique mid-tier ODMs around Anyang, Hwaseong, and Hwasung-eup show up in the sample. Specific cost ranges are illustrative of what we see in current quotations, not a published rate card.
What a Korean ODM Quote Actually Looks Like
Before we talk about which lines move, founders need a shared mental model of the document itself. A typical 2026 Korean ODM quote from a mid-tier partner has two surfaces.
The first surface is the per-unit production economics. Per-unit cost in USD or KRW, MOQ for the first run, payment terms (often 30 percent deposit on PO and 70 percent on shipment, sometimes 50/50, occasionally LC at sight for larger orders), Incoterms (usually FOB Busan or EXW Seoul), and an Estimated Time of Departure window between 75 and 110 days from approved sample plus deposit.
The second surface is the project-level engagement costs. Formulation fee (or "development fee"), sample fee per round, stability testing fee, primary packaging tooling if applicable, secondary packaging design and dieline fee if applicable, and regulatory documentation (KFDA functional notification, MoCRA registration support, EU CPNP file preparation, CPSR if your launch market includes the UK).
Most negotiable lines live on the second surface. Most fixed lines live on the first. The reason is straightforward. Per-unit production costs are gross-margin-tight for the ODM, especially at low MOQ. Project-level fees are essentially services revenue, where the ODM has more flexibility because there is no raw material at risk.
Read every quote with that two-surface model in mind. Mark each line as production-side or project-side before you decide where to push.
The 9 Lines With Real Bargaining Room
1. Sample Round Cap and Cost Per Round
Most Korean ODM quotes price samples at $250 to $600 per sample round depending on complexity and on whether the formulation already exists as a base. The negotiable element here is not always the price per round. It is the cap.
Many founders accept "we will charge sample fees per round" without writing a ceiling into the engagement. Three rounds of sample tweaks at $450 each is $1,350, and that is reasonable. Twelve rounds (which happens when the founder is changing direction repeatedly) is $5,400 and feels punitive. Negotiate a cap. The phrasing we use is "we agree to sample fees of $X per round up to four rounds; rounds five through eight will be charged at half rate; anything beyond round eight requires written re-scoping." That language is fair to both sides, signals operational discipline, and protects against runaway sample cost.
2. Formulation Fee, Stage-Gated
Formulation fees on a from-scratch indie brief usually fall in the $4,000 to $9,000 range for a single SKU at a mid-tier Korean ODM. For a four-SKU launch with shared base technology (think a barrier set with cleanser, toner, serum, cream), the total formulation fee should be discounted relative to four times the single-SKU rate. We typically see 18 to 28 percent total fee reduction for shared-base SKU bundles.
The negotiation move is not "lower the fee." It is "stage-gate the fee." Ask for the formulation fee to release in three installments tied to milestones. One third at brief acceptance, one third at sample round one approval, one third at final sample sign-off and start of stability. This protects you against a partner who underperforms after taking the full fee, and most Korean ODMs accept stage-gating without resistance because it signals that the founder takes contractual hygiene seriously.
3. Stability Testing Package Scope
Stability testing fees for a single SKU under ICH Q1A(R2) accelerated conditions (40°C / 75% RH for three months) plus ISO 11930 challenge testing, ISO 17516:2014 microbial limits, and freeze-thaw cycling typically land between $1,400 and $3,200 in current Korean ODM quotations.
The line you can negotiate is not the price; it is the scope. Most ODMs default to running the full package on every SKU even when SKUs share the same base formula and primary packaging material. If you are launching four SKUs that share a base, you can sometimes consolidate stability testing into one full package plus three compressed packages, dropping perhaps $2,000 to $4,500 off the total stability bill at the four-SKU level. The script is "since SKU 2, 3, and 4 share the same base emulsion and use identical primary packaging material with only color, scent, and one or two actives differing, can we propose a reduced stability protocol on the three derivative SKUs and reserve the full ICH Q1A(R2) accelerated package for the lead SKU."
The ODM may push back. That is fine. The point of the conversation is to identify which tests in the package are duplicative.
4. MOQ at the First Run, With Reorder Logic
Most Korean mid-tier ODMs publish a first-run MOQ of 3,000 to 5,000 units per SKU. Boutique partners in Anyang and Hwaseong will go to 1,000 or 1,500 on stock base formulas. The lever here is not the MOQ number alone. It is the relationship between first-run MOQ and second-run MOQ.
Ask for a first-run MOQ commitment of 1,000 to 1,500 units (boutique tier) or 2,000 units (mid-tier) in exchange for a contractual second-run commitment of 3,000 units within six months of the first shipment landing in your warehouse. The ODM gets the volume comfort of seeing two POs in their forecast. You get the de-risked first-run that lets you validate sell-through before committing more cash. We negotiate this structure in roughly 6 of 10 indie engagements and it sticks more often than founders expect.
5. Packaging Tooling Amortization
Custom primary packaging molds (a tube with a distinctive cap, a uniquely shaped airless pump, a custom cushion compact) carry tooling costs of $3,000 to $18,000 depending on complexity and on whether the mold belongs to the packaging supplier or to you.
The lever is amortization. Many founders accept the full tooling cost on the first run. Better practice is to amortize the tooling cost across a contractual run of three to five POs, with each PO carrying a portion. This converts a $9,000 lump into a per-unit add of roughly $0.60 across 15,000 units (5,000 each PO across three POs). It also creates a soft retention mechanic for the ODM because they now have an incentive to keep you happy through PO three.
Be careful here. You want the tooling to remain assigned to your brand, not to the ODM. Write that into the agreement explicitly. The phrasing is "tooling cost amortized across POs 1 through 3, with mold ownership assigned to [Brand Entity LLC] upon full amortization and held in safekeeping by the ODM during the engagement."
6. Packaging Component Substitution
Indie founders almost always accept the packaging spec from the ODM's preferred vendor. That vendor is usually one of three or four Korean packaging houses (think Anyang, Hwaseong) that the ODM has standing relationships with. The quoted packaging cost is typically marked up 15 to 35 percent over the ex-factory packaging price.
You have two negotiation moves. The first is to ask for the packaging vendor's name and an option to procure direct, with the ODM charging only an integration handling fee (usually 5 to 8 percent) instead of the embedded markup. Some ODMs decline; some accept. The second move, if direct procurement is declined, is to ask for a 5 to 10 percent packaging discount in exchange for committing to the ODM's preferred vendor across the launch SKU set. Either move can save $0.30 to $0.90 per unit on packaging on a 3,000-unit run.
7. Regulatory Documentation Bundle
KFDA functional cosmetic notification (if your SKU makes whitening, anti-wrinkle, sunscreen, hair growth, or other functional claims), MoCRA cosmetic facility registration and product listing support, EU CPNP file preparation, and UK SCPN translation are each often quoted as separate line items at $1,200 to $4,500 per market.The negotiation move is to ask for a bundle rate. A founder who is launching in US, Korea, and EU simultaneously is buying three regulatory packages from the ODM, and three separate rates leave money on the table. Ask for a single global regulatory bundle at 20 to 30 percent below the sum of the individual rates, in exchange for naming the ODM as your sole regulatory documentation partner across markets. Most ODMs accept this because consolidating regulatory work into one bundle improves their internal workflow and locks in the engagement.
8. Payment Terms and Currency
A 30/70 deposit-on-PO, balance-on-shipment structure is standard. The negotiable elements are three.
First, the currency. Korean ODMs invoice in USD or KRW depending on the partner. If you bill in USD but your customer base is GBP-denominated (UK launch), ask whether the ODM will accept GBP at the spot exchange rate fixed on a named date. Some will, particularly for repeat engagements.
Second, the deposit percentage. A first-time founder with a clean limited liability structure can often negotiate the deposit from 30 percent down to 20 or even 15 percent on second and subsequent POs once a payment history is established. This is a reorder-relationship lever, not a first-PO ask.
Third, the holdback. Ask for a 5 to 10 percent holdback on shipment payment that releases 30 days after landed warehouse arrival in your country. This protects you against an inbound quality issue that only surfaces after customs clearance. Roughly half of Korean ODMs accept this; the other half offer a quality guarantee program instead, which is also acceptable.
9. Lead Time Buffer and Late Delivery Credit
Lead times in 2026 are running 80 to 110 days from approved sample plus deposit to FOB Busan dispatch for most mid-tier Korean ODMs, with boutique tier sometimes faster on simple base formulas. Cosmax and Kolmar tier-one queues run longer, often 100 to 130 days when their order book is full.
The negotiable line is a late delivery credit. Ask for a 1 to 2 percent per-week production credit if FOB dispatch slips more than two weeks past the quoted Estimated Time of Departure. Most Korean ODMs will accept a 0.5 to 1 percent per-week credit capped at 10 percent of the production invoice. This is not punitive; it is a structural way to keep both sides accountable to the timeline and to give the ODM operational urgency to honor the date.
"I'm Liz, the founder of ALTA MEET. I run our consulting practice from Manhattan, NYC, with the Korean partner side handled out of Seoul. I have read quotes from Cosmax, Kolmar, CTK, Cosmecca, and somewhere north of 20 boutique partners, and I will say the same thing every time. The line items you wish you had pushed on are the ones that are easiest to push on. If you want me to read your first or second Korean ODM quote with you before you sign, grab 15 minutes free with Liz. No pitch. We just go through the lines."
The 4 Lines That Are Essentially Fixed
Knowing where not to push is as valuable as knowing where to push. These four lines are essentially fixed and the only thing you accomplish by pushing on them is signaling inexperience.
Raw Material Cost on Premium Actives
If your brief specifies licensed PDRN at 1 to 2 percent, ceramide NP at 0.5 to 1 percent, encapsulated retinol at 0.05 to 0.1 percent, or trade-named peptide complexes from KCI, Lipotec, or Croda, the Korean ODM is buying that raw material at the supplier's published wholesale rate plus a small handling margin. The ODM is not marking up the raw material meaningfully. A founder who pushes on "can you lower the ceramide line" gets a politely confused response from the lab.
What you can do, and should do, is ask whether a functionally equivalent ingredient at a lower cost tier exists. A request like "can we model the formulation with a generic ceramide NP at the equivalent inclusion rate instead of the supplier's licensed grade" is a legitimate ask. Pushing on the cost itself is not.
Korean Lab and Testing Body Pass-Through Fees
In vivo SPF testing at a KFDA-recognized lab, patch testing at a Korean dermatology research center, microbial testing at SGS Korea or Eurofins CRL, and HRIPT testing in the US are pass-through costs from third-party labs. The ODM books the lab, the lab invoices the ODM, and the ODM passes the cost to you with at most a 5 to 8 percent administrative add. Pushing on these costs accomplishes nothing because the ODM has no margin to give.
If the testing line feels high, the question is not "can we lower the SPF testing fee" but "can we change the test design to a smaller panel or run the screening in vitro first." That second question gets you real savings; the first wastes a meeting.
KFDA Functional Notification Government Pass-Through
KFDA functional cosmetic notification itself is a government filing without a fee, but the supporting clinical data package (which is what most founders are actually paying for when they see a $25,000 to $80,000 "functional registration" line) is a hard cost driven by clinical trial protocols set by KFDA. The MFDS efficacy data requirements for anti-wrinkle, whitening, and SPF claims are codified. There is no margin to negotiate on the clinical work itself.
What you can negotiate is whether you need a functional claim at all. Many indie founders default to "anti-wrinkle" when "fine-line appearance" or "smoothing" would carry equivalent consumer impact at zero regulatory cost. That conversation is a brief decision, not a quote negotiation.
The ODM's Internal QC and ISO 22716 GMP Overhead
A Korean ODM running an ISO 22716 KGMP-certified facility carries a substantial overhead in quality control, batch documentation, raw material qualification, and surveillance audit preparation. That overhead is allocated across every unit produced, and it is typically a flat per-unit add (often $0.08 to $0.18 per unit at standard MOQ tiers).
Trying to negotiate this line down is functionally trying to negotiate the GMP certification itself. The ODM cannot move it without compromising their own audit posture. Recognize it for what it is, factor it into your unit cost, and move on. A founder who pushes on the QC line tells the ODM that they may eventually push the lab to take quality shortcuts. That perception cannot be unwound.
How to Phrase the Ask: Three Negotiation Scripts
Negotiation language matters at Korean ODMs. The Seoul-side product manager is reading your email through a cultural register where directness can read as aggression and indirectness can read as confusion. We give founders three scripts.
The first script is the framing script. Open by acknowledging the work the ODM has put in. "Thank you for the detailed quote. We reviewed it carefully and have a small number of structural questions we would like to discuss." This signals respect and primes the conversation as collaborative.
The second script is the bundled-ask script. Rather than negotiating each line individually, send a single email with three to five proposed adjustments framed as a package. "We would like to propose the following adjustments to the quote, taken together: (1) sample rounds capped at 4 standard plus 4 half-rate; (2) formulation fee released in three milestones; (3) stability testing consolidated on shared-base SKUs; (4) tooling amortized across POs 1 through 3; (5) regulatory bundle rate for US, Korea, and EU together." A bundled ask lets the ODM concede on some lines while holding others, which is how Korean B2B negotiations actually work.
The third script is the walk-away language. If a critical lever is non-negotiable and the partner is unwilling to discuss alternatives, "we appreciate the detail and the time, and we are going to take this back to internal review before we commit" buys you the room to compare quotes from a second ODM without burning the first relationship. Korean ODMs respect founders who pause to compare; they distrust founders who rush to sign.
When to Walk Away: Three Hard Signals
There are three signals that mean the partner is structurally wrong for you regardless of how the negotiation goes.
The first is opacity on raw material sourcing for actives. If you ask "which supplier and grade of niacinamide is in this serum" and you get a vague answer or a deflection, the ODM either does not know or does not want to tell you. Either case is a reason to look elsewhere. Korean ODMs that are confident in their supply chain answer this question in a single sentence.
The second is inability to produce a KGMP audit report from the past 18 months on request. ISO 22716 surveillance audits happen annually. A facility in good standing has a recent report to share, even in redacted form. A facility that cannot produce one or that produces one with significant unresolved non-conformities is a quality risk that no price discount makes up for.
The third is unwillingness to put MoCRA, KFDA, or EU regulatory responsibilities in writing. Indie founders sometimes assume the ODM will "handle the FDA stuff." That assumption causes real legal exposure. The ODM may file or may not file; the responsibility flows to the brand owner. If the partner will not write out who is responsible for what regulatory step and when, the engagement carries hidden risk.
Common Negotiation Mistakes: Five Patterns We See
The first mistake is negotiating before reading the full quote. Founders see a per-unit number that looks high, immediately push back on it, and miss that the high per-unit number includes packaging the founder could have direct-procured for 25 percent less. Read every line first.The second mistake is negotiating on cost when the real lever is volume. A 3,000-unit first run quoted at $4.70 per unit may drop to $3.85 per unit at 5,000 units. If your sell-through model supports 5,000 units, the volume conversation gets you more than the cost conversation. We help founders model this with their actual landed cost stack.
The third mistake is anchoring on a competitor quote without disclosing it. A founder who says "we have another ODM offering this at $3.40" without showing the comparison quote loses credibility. If you have a real competitor quote, share the relevant lines; if you do not, do not bluff.
The fourth mistake is conflating sample fees and tooling fees. Sample fees are operational and recurrent. Tooling fees are capital and one-time. Pushing on tooling as if it were a sample line tells the Seoul-side that you have not done the homework.
The fifth mistake, and the most expensive, is signing the first quote because the founder is afraid the ODM will lose patience if there is back-and-forth. Korean ODMs expect negotiation. The Seoul product manager has run this conversation hundreds of times. Doing the work signals seriousness, not nuisance.
The 30-60-90 Day Negotiation Calendar
Negotiation does not happen in a single email. It runs across roughly 90 days from first quote to signed PO.
Days 1 through 14 are quote review. Sit with the quote, build a cost model in a spreadsheet with every line broken out, identify the 9 negotiable lines and the 4 fixed lines for your specific brief, and prepare your bundled ask.
Days 15 through 35 are the negotiation phase. Send the bundled ask, take the reply meeting, work through revisions. Expect two to three rounds. If the ODM is unresponsive past round one, that is itself a signal.
Days 36 through 60 are the contracting phase. The quote that you sign at the end of negotiation becomes the basis of the Master Supply Agreement. Make sure the negotiated terms make it into the contract; many founders are surprised that the contract text reverts to the original quote terms if no one re-reads the document with the agreed amendments in hand.
Days 61 through 90 are the deposit-to-sample phase. The first sample arrives. If the ODM honored the spec in the brief and the negotiation held, you have a real partner. If they cut corners on the spec or pushed back on lines that were settled, you have a problem to address before mass production.
This calendar applies to founders working without a consulting partner. If you want a second set of eyes on a quote you have just received, the Calendly link in the founder note above is the fastest path.
Key Takeaways
A Korean ODM quote has two surfaces. Per-unit production economics are mostly fixed; project-level engagement fees are mostly negotiable. Read the quote with that split in mind.
Nine lines have real bargaining room: sample round cap and cost per round, formulation fee stage-gating, stability testing scope, MOQ at first run with reorder logic, packaging tooling amortization, packaging component substitution, regulatory documentation bundling, payment terms and currency, and lead time buffer plus late delivery credit.
Four lines are essentially fixed: raw material cost on premium actives, Korean lab and testing body pass-through fees, KFDA functional notification government pass-through, and the ODM's internal QC and ISO 22716 GMP overhead. Pushing here signals inexperience.
Use a bundled-ask script rather than line-by-line negotiation. Korean B2B norms favor packaged discussions over single-line pushback.
Three hard signals mean walk away regardless of price: opacity on raw material sourcing, inability to produce a recent KGMP audit report, and unwillingness to write regulatory responsibilities into the agreement.
Negotiate at the volume conversation level, not just the per-unit cost level. Volume often unlocks more savings than direct unit-price pushback.
The negotiated terms must make it into the Master Supply Agreement. Do not assume the contract carries forward your verbal agreements.
Frequently Asked Questions
How much should I expect to save from a clean Korean ODM quote negotiation? In our practice, indie K-beauty founders save roughly $6,000 to $18,000 on a first-launch engagement of two to four SKUs at 3,000-unit MOQs. Most of the savings come from stability testing consolidation, packaging tooling amortization, and regulatory bundle pricing rather than per-unit cost compression.
Will my Korean ODM raise the per-unit price if I negotiate aggressively on project fees? Sometimes, but rarely in the way founders fear. A Korean ODM may decline some of your asks rather than retaliate on unit price. The risk is mostly relational, not numerical. Bundled asks with respectful framing carry the lowest risk.
Should I share competitor quotes during negotiation? Only if they are real and only if you are willing to show them. Bluffing is detectable. If you have a comparable quote from a second ODM at meaningfully better terms on specific lines, sharing those lines anonymously can move the conversation. Naming the competitor publicly is not common practice and tends to cool the relationship.
Can I negotiate after I have already signed? Limited room. The Master Supply Agreement governs once signed. The exceptions are amendments tied to volume increases (negotiate down on per-unit cost as you raise MOQ), to additional SKU additions (negotiate bundled formulation fees on the second wave), and to scope expansions (regulatory work added later can be re-bundled). A clean engagement structure makes future amendments easier.
What if the ODM refuses to put regulatory responsibilities in writing? That is one of the three walk-away signals. The MoCRA "responsible person" designation in the US, the KFDA holder-of-record requirement in Korea, and the EU CPNP responsible person obligation are all enforceable regulatory positions. Ambiguity here is a real exposure for the brand owner. If a partner will not write out who handles what and when, find a different partner.
What is a fair lead time buffer to ask for? A 0.5 to 1 percent per-week production credit, capped at 10 percent of the production invoice, kicking in two weeks past the quoted Estimated Time of Departure, is standard. Larger Korean ODMs sometimes structure this as a delivery guarantee program with priority queue placement instead of a credit. Either approach is acceptable.
Do boutique Korean ODMs negotiate differently from Cosmax and Kolmar? Yes. Boutique partners in Anyang, Hwaseong, and the smaller Seoul-area facilities have more flexibility on MOQ and project fees but less flexibility on lead time because their order book recovers slowly from disruption. Cosmax, Kolmar, and the tier-one houses have more flexibility on lead time predictability and bundled pricing across multi-SKU engagements but less flexibility on first-run MOQ. Match your negotiation focus to the partner tier.
Working With ALTA MEET
ALTA MEET is a New York City consultancy that helps US indie K-beauty founders run cross-border engagements with Korean ODMs. We read quotes alongside founders, negotiate the lines that matter, and stay on the call during Seoul-side product reviews. If you have a Korean ODM quote in hand and you want a structured second opinion before you sign, book your free 15-min K-Beauty manufacturing gut-check with Liz. We also publish related ALTA MEET reading you may find useful:
Reviewed for accuracy by ALTA MEET's formulation and sourcing team. Cost figures and timing reflect typical 2025 to mid-2026 Korean ODM quotations across the boutique, mid-tier, and tier-one segments. Numerical ranges are illustrative and not a substitute for partner-specific quote review.
References
ISO 22716:2007, Cosmetics Good Manufacturing Practices
ICH Q1A(R2), Stability Testing of New Drug Substances and Products (40°C / 75% RH accelerated conditions)
ISO 11930:2019, Cosmetics Microbiological Evaluation of Preservative Efficacy
ISO 17516:2014, Cosmetics Microbiological Limits
Regulation (EC) No 1223/2009, EU Cosmetic Product Notification Portal (CPNP)
MoCRA (Modernization of Cosmetics Regulation Act of 2022), 21 U.S.C. § 364 et seq., FDA Cosmetics Direct portal
KFDA Cosmetics Act, functional cosmetic notification framework, Ministry of Food and Drug Safety, Republic of Korea
